Liquidia Q2 Results: Sales surge 1,840% YoY to $171.679M

1 min read     Updated on 12 Aug 2026, 06:29 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Liquidia’s Q2 results show a dramatic recovery with EPS of $0.74 beating estimates by 80.49% and sales of $171.679M up 1,840% YoY. The company moved from a loss of $(0.49) per share to profitability, significantly outperforming analyst expectations for both metrics.

powered bylight_fuzz_icon
48085142

*this image is generated using AI for illustrative purposes only.

Liquidia (NASDAQ: LQDA) delivered a robust second-quarter performance, reporting earnings per share of $0.74 and quarterly sales of $171.679 million. The results significantly outperformed market expectations, with earnings beating the analyst consensus estimate of $0.41 by 80.49 percent and sales surpassing the projected $116.675 million by 47.14 percent. This strong showing marks a dramatic turnaround for the company, which reported a loss of $(0.49) per share in the same period last year, representing a 251.02 percent improvement. The revenue jump is even more pronounced, rising 1,840 percent year-over-year from just $8.837 million in the prior-year quarter.

Financial Performance Overview

The company’s ability to exceed both earnings and revenue estimates signals accelerating commercial traction and operational efficiency. The wide margin between actual results and analyst projections suggests that recent business developments may have been underappreciated by the market prior to the filing.

Metric Actual Estimate Variance YoY Change
Earnings Per Share $0.74 $0.41 +80.49% +251.02%
Quarterly Sales $171.679 million $116.675 million +47.14% +1,840%

What the Numbers Show

The most striking aspect of Liquidia’s Q2 results is the sheer scale of revenue growth compared to the prior year. A 1,840 percent increase in sales indicates that the company has likely scaled its commercial operations or secured significant new contracts that were not present twelve months ago. While the earnings beat of 80.49 percent is substantial, the revenue explosion suggests that top-line growth is the primary driver of this quarter’s success. The transition from a per-share loss of $(0.49) to a profit of $0.74 further underscores the operational leverage achieved as sales volumes expanded. Investors should note that while the absolute dollar increase in EPS is $1.23, the percentage change reflects the small base effect of the previous loss, highlighting the volatility inherent in this growth phase.

What specific new contracts or commercial partnerships drove the 1,840% year-over-year revenue surge, and are these deals recurring or one-time in nature?

How sustainable is the current operational leverage as sales volumes expand, and will gross margins remain stable or improve in subsequent quarters?

Will Liquidia adjust its full-year guidance upward given the significant beat on both earnings and sales estimates for Q2?

like17
dislike

Liquidia Corporation Q2 Results: Earnings date set for August 12, 2026

1 min read     Updated on 29 Jul 2026, 08:25 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Liquidia Corporation will release its second quarter 2026 financial results on August 12, 2026, accompanied by a live webcast at 8:30 a.m. ET. The company, known for its PRINT™ technology and products like YUTREPIA™, will discuss financial performance and corporate updates. An archived version of the webcast will be available for one year.

powered bylight_fuzz_icon
46882487

*this image is generated using AI for illustrative purposes only.

Liquidia Corporation (NASDAQ: LQDA) announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. The biopharmaceutical company, which focuses on respiratory and vascular diseases, will host a live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a broader corporate update. This disclosure sets the timeline for investors to assess the company’s operational and financial performance for the period ending June 30, 2026.

The webcast will be streamed live on Liquidia’s investor relations page at https://liquidia.com/investors/events-and-presentations . Following the live event, a rebroadcast of the presentation will be archived at the same location for a period of one year, ensuring continued access for stakeholders who cannot attend the initial broadcast.

Corporate Overview

Liquidia Corporation operates as a biopharmaceutical entity driven by science to revolutionize care for patients with challenging respiratory and vascular diseases. The company leverages its proprietary PRINT™ technology to develop precise, innovative therapies. Key products in its portfolio include YUTREPIA™ (treprostinil) inhalation powder, which is approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

In addition to its marketed therapies, Liquidia is actively developing L606, an investigational extended-release formulation of treprostinil administered twice daily using a next-generation nebulizer. The company also currently markets generic Treprostinil Injection for the treatment of PAH, maintaining a diversified approach within the pulmonary hypertension therapeutic area.

Investor and Media Contacts

For inquiries regarding the financial results and investor relations matters, Jason Adair, Chief Business Officer, is the designated contact point. He can be reached at 919.328.4350 or via email at jason.adair@liquidia.com . Media-related questions should be directed to media@liquidia.com .

Contact Role Name Details
Investors Jason Adair Chief Business Officer, 919.328.4350, jason.adair@liquidia.com
Media N/A media@liquidia.com

What the Numbers Show

While specific financial metrics for Q2FY26 are not yet disclosed, the announcement confirms the company’s adherence to standard reporting cycles. The upcoming webcast will likely detail revenue trends from YUTREPIA™ and generic Treprostinil Injection, as well as progress on the development of L606. Investors should monitor the August 12 presentation for updates on clinical trials, regulatory milestones, and cash position, which are critical indicators for biopharmaceutical firms in the growth phase.

How might the Q2 2026 revenue performance of YUTREPIA influence Liquidia's valuation relative to competitors in the pulmonary hypertension market?

What specific clinical milestones for the investigational drug L606 are investors likely to prioritize during the August 12 webcast?

Could changes in the cash position reported in Q2 impact Liquidia's ability to fund future Phase 3 trials without seeking additional capital?

like16
dislike

More News on Liquidia Corp